Robert Knoerl1, Evan Gray2, Carrie Stricker3, Sandra A Mitchell4, Kelsey Kippe5, Gloria Smith6, William N Dudley2, Ellen M Lavoie Smith7. 1. University of Michigan School of Nursing, Ann Arbor, MI, 48109, USA. rjknoerl@umich.edu. 2. School of Health and Human Sciences, Department of Health Education, University of North Carolina at Greensboro, Greensboro, NC, 27412, USA. 3. Carevive Systems Inc., Philadelphia, PA, 19104, USA. 4. National Cancer Institute, Outcomes Research Branch, Rockville, MD, 20850, USA. 5. Northwestern Memorial Hospital, Chicago, IL, 60611, USA. 6. University of Michigan Health System, Ann Arbor, MI, 48109, USA. 7. University of Michigan School of Nursing, Ann Arbor, MI, 48109, USA.
Abstract
PURPOSE: The aim of this study is to examine and compare with the validated, paper/pencil European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20), the psychometric properties of three electronically administered patient reported outcome (PRO) measures of chemotherapy-induced peripheral neuropathy (CIPN): (1) the two neuropathy items from the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), (2) the QLQ-CIPN20, and (3) the 0-10 Neuropathy Screening Question (NSQ). METHODS: We employed a descriptive, cross-sectional design and recruited 25 women with breast cancer who were receiving neurotoxic chemotherapy at an academic hospital. Participants completed the paper/pencil QLQ-CIPN20 and electronic versions of the QLQ-CIPN20, PRO-CTCAE, and NSQ. Internal consistency reliability, intraclass correlation, and concurrent and discriminant validity analyses were conducted. RESULTS: The alpha coefficients for the electronic QLQ-CIPN20 sensory and motor subscales were 0.76 and 0.75. Comparison of the electronic and paper/pencil QLQ-CIPN20 subscales supported mode equivalence (intraclass correlation range >0.91). Participants who reported the presence of numbness/tingling via the single-item NSQ reported higher mean QLQ-CIPN20 sensory subscale scores (p < 0.001). PRO-CTCAE neuropathy severity and interference items correlated well with the QLQ-CIPN20 electronic and paper/pencil sensory (r = 0.76; r = 0.70) and motor (r = 0.55; r = 0.62) subscales, and with the NSQ (r = 0.72; r = 0.44). CONCLUSION: These data support the validity of the electronically administered PRO-CTCAE neuropathy items, NSQ, and QLQ-CIPN20 for neuropathy screening in clinical practice. The electronic and paper/pencil versions of the QLQ-CIPN can be used interchangeably based on evidence of mode equivalence.
PURPOSE: The aim of this study is to examine and compare with the validated, paper/pencil European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20), the psychometric properties of three electronically administered patient reported outcome (PRO) measures of chemotherapy-induced peripheral neuropathy (CIPN): (1) the two neuropathy items from the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), (2) the QLQ-CIPN20, and (3) the 0-10 Neuropathy Screening Question (NSQ). METHODS: We employed a descriptive, cross-sectional design and recruited 25 women with breast cancer who were receiving neurotoxic chemotherapy at an academic hospital. Participants completed the paper/pencil QLQ-CIPN20 and electronic versions of the QLQ-CIPN20, PRO-CTCAE, and NSQ. Internal consistency reliability, intraclass correlation, and concurrent and discriminant validity analyses were conducted. RESULTS: The alpha coefficients for the electronic QLQ-CIPN20 sensory and motor subscales were 0.76 and 0.75. Comparison of the electronic and paper/pencil QLQ-CIPN20 subscales supported mode equivalence (intraclass correlation range >0.91). Participants who reported the presence of numbness/tingling via the single-item NSQ reported higher mean QLQ-CIPN20 sensory subscale scores (p < 0.001). PRO-CTCAE neuropathy severity and interference items correlated well with the QLQ-CIPN20 electronic and paper/pencil sensory (r = 0.76; r = 0.70) and motor (r = 0.55; r = 0.62) subscales, and with the NSQ (r = 0.72; r = 0.44). CONCLUSION: These data support the validity of the electronically administered PRO-CTCAE neuropathy items, NSQ, and QLQ-CIPN20 for neuropathy screening in clinical practice. The electronic and paper/pencil versions of the QLQ-CIPN can be used interchangeably based on evidence of mode equivalence.
Authors: Robert Knoerl; William N Dudley; Gloria Smith; Celia Bridges; Grace Kanzawa-Lee; Ellen M Lavoie Smith Journal: Comput Inform Nurs Date: 2017-04 Impact factor: 1.985
Authors: Floortje Mols; Tonneke Beijers; Gerard Vreugdenhil; Lonneke van de Poll-Franse Journal: Support Care Cancer Date: 2014-05-01 Impact factor: 3.603
Authors: Kathleen A Griffith; Ingemar S J Merkies; Elizabeth E Hill; David R Cornblath Journal: J Peripher Nerv Syst Date: 2010-12 Impact factor: 3.494
Authors: Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch Journal: Qual Life Res Date: 2013-07-20 Impact factor: 4.147
Authors: Thomas M Atkinson; Sean J Ryan; Antonia V Bennett; Angela M Stover; Rebecca M Saracino; Lauren J Rogak; Sarah T Jewell; Konstantina Matsoukas; Yuelin Li; Ethan Basch Journal: Support Care Cancer Date: 2016-06-03 Impact factor: 3.603
Authors: Ellen M Lavoie Smith; Tanima Banerjee; James J Yang; Celia M Bridges; Paola Alberti; Jeff A Sloan; Charles Loprinzi Journal: Cancer Nurs Date: 2019 May/Jun Impact factor: 2.592
Authors: Tiffany Li; Susanna B Park; Eva Battaglini; Madeleine T King; Matthew C Kiernan; David Goldstein; Claudia Rutherford Journal: Qual Life Res Date: 2022-05-21 Impact factor: 3.440
Authors: Ellen M Lavoie Smith; Robert Knoerl; James J Yang; Grace Kanzawa-Lee; Deborah Lee; Celia M Bridges Journal: Cancer Control Date: 2018 Jan-Mar Impact factor: 3.302